EMSAM (deprenyl patch): how a promising antidepressant was underutilized [Corrigendum]

Abstract

Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”. The authors apologize for these errors.Read the original article